Evaluation of Renal Function in Patients with Atrial Fibrillation received Warfarin compared with Aspirin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240509001

Enrollment

360

Registered

2024-05-09

Start date

2023-08-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Change in glomerular filtration rate in patient with AF after received Warafrin and Aspirin Atrial Fibrillation, Glomerular Filtration Rate, Warfarin, Aspirin

Interventions

Sample group of AF patients receiving Warfarin,Sample group of AF patients receiving Aspirin

Other,Other

The group receiving Warfarin,The group receiving Aspirin

Eligibility

Sex/Gender

All

Age

30 Years to 95 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with Atrial Fibrillation (AF) who received treatment from 1 January 2020 to 31 March 2023, regardless of age and gender. and was treated with Warfarin and Aspirin.

Exclusion criteria

Exclusion criteria: Patients with co-morbidities that have the potential to cause kidney complications or kidney deterioration, such as Systemic Lupus Erythematosus (SLE), Autoimmune Disease, Uncontrolled Hypertension, Uncontrolled Diabetes Mellitus, Uncontrolled Hyperlipidemia

Design outcomes

Primary

Measure	Time frame
percentage change of GFR 1 year laboratory test	—

Secondary

Measure	Time frame
other factors affecting the change of gfr 1 year laboratory test	—

Countries

Thailand

Contacts

Public ContactPisut Greetanukroh

Pharpokklao Hospital

POM042@GMAIL.COM0925950959

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026